Milestones
Antoine Verslype appointed Laboratory Manager
10th April 2015
Dr Pete Appleford appointed Research Fellow
18th November 2014
Scale-up Doubles Screening Capacity
17th June 2014
Sibelius Signs Screening Contract with Cape Kingdom
17th April 2014
9 Sibelius Proprietary Products Developed
6th October 2013
Sibelius Signs Contract with Creeyan
1st August 2013
Type II Diabetes Mellitus Screening
30th July 2013
Development of Third Proprietary Product
18th February 2013
High Through-Put Mechanism of Action Screening
14th January 2013
Novel Proprietary Anti-Ageing Compound Discovered
10th October 2012
Development of Second Proprietary Product
17th September 2012
Successful Synergistic Combinations Identified
10th September 2012
Development of Proprietary Product
17th August 2012
Novel Proprietary High Throughput Screening Developed
13th August 2012
Review Validates Sibelius’ Therapeutic Approach
11th February 2012
Eu Yang San Testing & Development Agreement
28th October 2011
Development of Sibelius Proprietary Formulation
6th October 2011
Health and Wellness Innovations signs Licence Agreement with Sibelius
20th September 2011
Eu Yan Sang Signs Development Contract with Sibelius
28th May 2011
RDC5 Reduces the Levels of Toxic Protein Aggregates
9th December 2010